Clinical Trial Spotlight
Hope for dry AMD?
How Anatomical Factors Can Affect Anti-VEGF Outcomes in AMD
Unique challenges can arise in these patients.
Innovation In Retina
Daniel M. Schwartz, MD: UCSF and Caltech
Multimodal Imaging in Idiopathic Juxtafoveolar Retinal Telangiectasia
More than one imaging modality is often needed.
New Insights on Drug Retinopathy and Enhanced-Depth Imaging
The 52nd annual Walter Wright Ophthalmology and Vision Sciences Symposium offers the latest in ophthalmic research.
Subspecialty News
Drug delivery into the suprachoroidal space; Europe approves Eylea for wet AMD; Carotenoids may reverse early AMD; Changes in genes a cause of AMD; and more
Surgical Treatment of Diabetic Macular Edema
Pathophysiological and clinical evidence with a proposed classification scheme
The Role of Vitrectomy in the Management of Posterior Uveitis
An overview of indications and two case studies.
Upfront: From the Editor-in-Chief
Keys and ‘Klout’
Anti-VEGF Therapies Continue to Impress
At the 2012 ASRS conference, several presentations illustrated how effective aflibercept can be in patients with recalcitrant disease.
By Michelle Dalton, ELS
Chronic, Persistent Fluid Treated with Aflibercept
By Karl G. Csaky, MD, Dallas, Texas
Suboptimal Responder Treated with Aflibercept
By Jeffrey S. Heier, MD
Summarizing the Key Anti-VEGF Study Results
Several comparison studies should help guide clinicians through the decision-making process.